Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449266 | 1.00 | HRH3 (0.46) | HRH3FFAR1ITKGPR119AR | |
| SCHEMBL437380 | 1.00 | HRH3 (0.46) | HRH3FFAR1ITKGPR119AR | |
| SCHEMBL799768 | 0.82 | ALDH1A1 (0.54) | FFAR1ALDH1A1KDM1A | |
| SCHEMBL13326647 | 0.81 | S1PR1 (0.41) | FFAR1ARKCNH2 | |
| SCHEMBL15314508 | 0.81 | SLC6A4 (0.45) | HRH3KDM1AKCNH2 | |
| SCHEMBL13859341 | 0.81 | SLC9A1 (0.50) | HRH3AR | |
| SCHEMBL12894946 | 0.81 | SLC9A1 (0.50) | ALDH1A1 | |
| SCHEMBL12894947 | 0.81 | SLC9A1 (0.50) | ALDH1A1 | |
| SCHEMBL804952 | 0.81 | SLC9A1 (0.50) | ALDH1A1 | |
| SCHEMBL440565 | 0.81 | SLC6A4 (0.45) | HRH3KDM1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164889-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-06-18 | — | — | US | disclosed |
| US-20150164888-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-06-18 | — | — | US | disclosed |
| US-8993577-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-03-31 | — | — | US | disclosed |
| EP-2398780-B1 | CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR | ASTRAZENECA AB (SE) | 2013-04-17 | — | — | EP | disclosed |
| EP-2398780-A1 | CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR | AstraZeneca AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| US-20110201622-A1 | Solid Forms Comprising A Cyclopropyl Amide Derivative | ASTRAZENECA PHARMACEUTICALS LP | 2011-08-18 | — | — | US | disclosed |
| US-20100216812-A1 | Cyclopropyl Amide Derivatives | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| WO-2010096011-A1 | CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201622-A1 | Solid Forms Comprising A Cyclopropyl Amide Derivative | SFPQ, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SBDS | HRH3 1977/4885FFAR1 2695/4885ITK 3144/4885 |
| US-20100216812-A1 | Cyclopropyl Amide Derivatives | HRH4, HRH2, HRH3 | HRH3 3/4885FFAR1 48/4885ITK 3236/4885 |
| US-20150164888-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | HRH3 3/4885FFAR1 48/4885ITK 3236/4885 |
| US-20150164889-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | HRH3 3/4885FFAR1 48/4885ITK 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.